A Phase 2 interventional study of NoNO-42 in Acute Ischemic Stroke, sponsored by NoNO Inc.. Recruiting at 9 sites in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by NoNO Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Ischemic Stroke with a site in Canada — 32 open to participants now, 39 under way, 9 of them phase 3. Ischemic Stroke · Canada.
Among the 117 studies in Ischemic Stroke with a site in Canada, this one is the 33rd largest by planned enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2024, is one of 17 in phase 2, reaches primary completion later than 11 of the 38 other live ones, and was the 100th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 117 studies in Ischemic Stroke with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 75+
Population Health Research Institute · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada, Australia
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States
Ages 18+
Javelin Medical · Sites in Canada, United States, Brazil and 1 more country
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 26 · Phase 4 7
First in 2000; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 275 across the 90 interventional studies, 275 across the 24 observational. Of the 71 that completed or were terminated, 25 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 117 have an industry lead sponsor. The 10 most frequent:
NoNO Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
NoNO Inc. has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
9 of the studies in Ischemic Stroke with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06403267NoNO Inc.NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy | 2026-12 |
| NCT05724823University of British ColumbiaVirtual Physical Activity Seated Exercise - Phase 2 | 2026-12-31 |
| NCT06027788Icahn School of Medicine at Mount SinaiCTSN Embolic Protection Trial | 2027-04-01 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 117 studies in Ischemic Stroke with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).
This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
Because AIS is a medical emergency, the trial is designed to enable the administration of standard-of-care treatments in order to save the life of the person concerned, restore good health and alleviate suffering.
A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well. Randomization will be 1:1 drug/placebo. Randomization will be stratified by large vessel occlusion (LVO) (yes/no) and a minimization algorithm to minimize the contribution of imbalances in baseline factors (age, sex, baseline NIHSS score). The design is adaptive with prospective rules for adaptive enrichment, in which enrollment may be restricted to participants without an LVO. LVO is defined as an occlusion of the intracranial ICA, M1 or proximal M2.
Randomized participants will receive/received an intravenous thrombolytic and be allocated to:
Day 90: All participants will be followed for 90 days (or until death if prior to 90 days) for efficacy and 30 days for safety. The end of the trial is defined as the date that all participants have completed their Day 90 contact.
1-Year follow Up: participants who completed the trial to Day 90 may be followed at 1 year for long-term efficacy.
One database lock and corresponding report for the trial to Day 90 and a separate database lock and analysis for the 1-year follow up are planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
8) Severe comorbid illness with less than 90 days, or likely to prevent completing 90-day follow-up.
9) Long term care facility resident or prisoner 10) Participation in another clinical trial outside of the ACT-GLOBAL platform investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding trial enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized participants will be given a single, 2.6 mg/kg 20-minute intravenous dose of NoNO-42 with a target start time of less than 10 minutes from randomization.
Drug: NoNO-42
a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
Reducing global disability in participants with acute ischemic stroke (AIS)
The primary outcome is the mRS at Day 90. The primary analysis of the primary outcome will be a "shift" analysis, which is an ordinal analysis across the mRS scale. The primary estimand is odds-ratio for a better outcome on the mRS scale for NoNO-42 compared to control.
Time frame: 90 days from intervention
Improving excellent functional outcome
Proportion of participants with a mRS of 0-1 at Day 90
Time frame: 90 days from intervention
Reducing worsening of stroke
Proportion of participants exhibiting a worsening of their index stroke during hospitalization. Worsening of stroke is defined as (A) progression of the index stroke or symptomatic intracranial, or symptomatic intracranial hemorrhagic within the first 7-days after randomization, supported and confirmed by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥ 4-point increase from lowest NIHSS during initial hospitalization or (B) results in death from the index stroke (i.e., index stroke is judged to be the principal cause of death) within the first 21-days after randomization.
Time frame: 90 days from intervention
Improving functional independence
Proportion of participants with a mRS of 0-2 at Day 90.
Time frame: 90 days from intervention
Reducing mortality rate
Proportion of participant mortality over the 90-day trial period
Time frame: 90 days from intervention
Improving health-related quality of life
Health-related quality of life, as measured by the EQ-5D-5L at Day 90
Time frame: 90 days from intervention
1 year Follow-up
Whenever possible, participants will be followed up to 1 year post stroke to determine the efficacy of NoNO-42 at 1 year post stroke in: • Reducing global disability in participants with acute ischemic stroke (AIS).- - proportion of participants with a shift of one or more categories to reduced functional dependence analyzed across the whole distribution of outcomes on the mRS Scale The secondary objectives are to determine the efficacy of NoNO-42 at 1 year post stroke in: * Improving excellent functional outcome - Proportion of participants with a mRS of 0-1 at 1-year. * Improving functional independence - Proportion of participants with a mRS of 0-2 at 1-year * Reducing mortality rate - Proportion of participant mortality over 1-year * Improving health-related quality of life - Health-related quality of life, as measured by the EQ-5D-5L at 1-year
Time frame: 1 year post intervention
Safety Outcome
safety of a single 2.6 mg/kg dose of intravenous NoNO- 42 based on: * Serious adverse events (SAEs) to Day 30 and * 90-day mortality.
Time frame: 30 and 90 days post intervention
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 26 months is close to that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NONO-42
NoNO Inc.